Drug intelligence / Profile preview

fasiglifam

Development stage: Discontinued
Lead developer: Takeda
Modality: Small Molecules
Administration: Oral

Overview

Fasiglifam is an orally available small molecule drug developed as a selective agonist and ago-allosteric modulator of the free fatty acid receptor 1 (FFAR1, also known as G-protein–coupled receptor 40 or GPR40). It was investigated primarily for the treatment of type 2 diabetes mellitus, where it demonstrated potent glucose-lowering effects by potentiating glucose-stimulated insulin secretion in a glucose-dependent manner. This mechanism offered advantages over sulfonylureas by reducing the risk of hypoglycemia. Fasiglifam reached phase III clinical trials for type 2 diabetes but its development was terminated due to concerns about liver safety. The drug was developed by Takeda[1][3][4][6][7][8].

Other names: fasiglifam

Targets

FFAR1 (Free fatty acid receptor 1)

Beyond the preview

Go deeper on fasiglifam.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fasiglifam.

Explore the full profile